Guardant Health (NASDAQ:GH) Price Target Raised to $56.00

Guardant Health (NASDAQ:GH) had its price target increased by research analysts at The Goldman Sachs Group from $49.00 to $56.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would indicate a potential upside of 31.34% from the company’s previous close.

GH has been the subject of several other reports. Stifel Nicolaus upped their price target on shares of Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a research report on Friday. Barclays assumed coverage on shares of Guardant Health in a research report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target for the company. JPMorgan Chase & Co. upped their price target on shares of Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday. Sanford C. Bernstein dropped their target price on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Finally, Guggenheim reiterated a “buy” rating on shares of Guardant Health in a report on Wednesday, January 22nd. Eighteen investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $44.78.

Guardant Health Stock Down 10.1 %

NASDAQ:GH traded down $4.76 during midday trading on Friday, hitting $42.64. The company had a trading volume of 2,764,364 shares, compared to its average volume of 2,474,979. Guardant Health has a 52-week low of $15.81 and a 52-week high of $50.89. The stock’s fifty day moving average price is $40.03 and its 200-day moving average price is $31.51. The company has a market capitalization of $5.27 billion, a PE ratio of -10.09 and a beta of 1.32.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. As a group, research analysts forecast that Guardant Health will post -3.39 earnings per share for the current year.

Insider Transactions at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the transaction, the director now owns 2,676 shares in the company, valued at $93,660. This trade represents a 46.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 2,652 shares of company stock worth $93,192 in the last 90 days. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Guardant Health

Several institutional investors and hedge funds have recently modified their holdings of GH. R Squared Ltd bought a new stake in Guardant Health in the 4th quarter valued at $26,000. JNBA Financial Advisors bought a new stake in Guardant Health in the 3rd quarter valued at $26,000. SBI Securities Co. Ltd. bought a new stake in Guardant Health in the 4th quarter valued at $43,000. Ashton Thomas Securities LLC bought a new stake in Guardant Health in the 3rd quarter valued at $34,000. Finally, Kimelman & Baird LLC bought a new stake in Guardant Health in the 4th quarter valued at $58,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.